Susceptibility Breakpoints for Amphotericin B and Aspergillus Species in anIn VitroPharmacokinetic-Pharmacodynamic Model Simulating Free-Drug Concentrations in Human Serum

Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model

(2014) M. Siopi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Single-Dose Pharmacodynamics of Amphotericin B against Aspergillus Species in anIn VitroPharmacokinetic/Pharmacodynamic Model

(2013) Rafal Al-Saigh et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroPharmacokinetic/Pharmacodynamic Modeling of Voriconazole Activity against Aspergillus Species in a NewIn VitroDynamic Model

(2012) R. Al-Saigh et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

EUCAST Technical Note on Aspergillus and amphotericin B, itraconazole, and posaconazole

(2012) M.C. Arendrup et al.   CLINICAL MICROBIOLOGY AND INFECTION

Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry

(2012) William J. Steinbach et al.   JOURNAL OF INFECTION

Amphotericin Bin vitroresistance is associated with fatalAspergillus flavusinfection

(2012) Inès Hadrich et al.   MEDICAL MYCOLOGY

Pharmacodynamic Effects of Simulated Standard Doses of Antifungal Drugs against Aspergillus Species in a NewIn VitroPharmacokinetic/Pharmacodynamic Model

(2011) Joseph Meletiadis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B and Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document)

(2011) A. Espinel-Ingroff et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update

(2010) J Maertens et al.   BONE MARROW TRANSPLANTATION

Concentrations of Voriconazole in Healthy and Inflamed Lung in Rats

(2009) C. Joukhadar et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Trends in antifungal susceptibility testing using CLSI reference and commercial methods

(2009) Emilia Cantón et al.   Expert Review of Anti-Infective Therapy

Patterns of Susceptibility of Aspergillus Isolates Recovered from Patients Enrolled in the Transplant-Associated Infection Surveillance Network

(2009) J. W. Baddley et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Dose-response relationships of three amphotericin B formulations in a non-neutropenic murine model of invasive aspergillosis

(2009) J. W. Mouton et al.   MEDICAL MYCOLOGY

Changes in causes of death over time after treatment for invasive aspergillosis

(2008) John R. Wingard et al.   CANCER

Amphotericin B lipid preparations: what are the differences?

(2008) J.P. Adler-Moore et al.   CLINICAL MICROBIOLOGY AND INFECTION